The launch time and approval progress of Asciminib in China

Asciminib (Asciminib) has been launched in China relatively recently and has now received domestic drug approval and officially entered the market. This means that patients who meet the indications can obtain the medicine through prescription at regular medical institutions, thereby providing new treatment options for patients with chronic myelogenous leukemia and other related diseases. Although the drug is already on the market, since it is a newly introduced targeted drug on the market, patients still need to consult a doctor in detail before taking the drug to understand its indications and possible adverse reactions.

In terms of approval progress, Aceminib has undergone rigorous clinical trial data review, including efficacy, pharmacokinetics and safety evaluation. The Chinese drug regulatory authorities referred to international clinical data and conducted a comprehensive evaluation based on the characteristics of domestic patients, and finally approved its use for the treatment of specific patients with chronic myelogenous leukemia. This also shows that the introduction of innovative targeted drugs in China is accelerating, providing patients with more treatment options.

In terms of price, Acemini is currently not included in the domestic medical insurance system, so patients need to bear all costs themselves. For specific prices, please consult the local hospital pharmacy. Since the drug is an imported drug, its price is usually higher, especially the European version of the original drug, which costs tens of thousands of yuan, which may bring certain financial pressure to some patients. When choosing medication, patients should make a full assessment based on their own financial situation and clinical needs.

In addition, there are Laotian generic drugs available in foreign markets. The price is more than 4,000 yuan, which is much cheaper than the original drug, and the drug ingredients are basically the same as the original drug. For patients with limited financial conditions, choosing generic drugs through formal channels can reduce the financial burden while ensuring the therapeutic effect. However, regardless of whether they choose original drugs or generic drugs, patients should take the drugs under the guidance of professional doctors to ensure safety and efficacy.

Reference materials:https://www.drugs.com/